Combination therapy with a molecular target drug and iron chelator for the treatment of intractable hepatocellular carcinoma

Combination therapy with a molecular target drug and iron chelator for the treatment of intractable hepatocellular carcinoma - Combination chemotherapy for the treatment of hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013461

Enrollment

Registered

2014-03-19

Start date

2014-03-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced hepatocellular carcinoma

Interventions

Sorafenib and deferasirox

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Sorafenib intractable hepatocellular carcinoma Child-Pugh A

Exclusion criteria

Exclusion criteria: active double cancers severe complications contraindication of the test drugs

Design outcomes

Primary

Measure	Time frame
safety and compliance	—

Secondary

Measure	Time frame
antitumor effect time to tumor progression overall survival effect to liver function and iron level	—

Countries

Japan

Contacts

Public ContactKazuhiro Nouso

Okayama University Hospital Gastroenterology

nouso@cc.okayama-u.ac.jp+81-86-235-7219

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026